# Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

> **NCT00503906** · PHASE2 · COMPLETED · sponsor: **University of Miami** · enrollment: 30 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Avastin
- **DRUG:** Gemcitabine
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT00503906
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503906, "Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00503906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*